Moreover, a combination of dasatinib with rapamycin or LY294002 decreases FOXO1/3 (forkhead box proteins O1 and O3) phosphorylation and drives the apoptosis of CML cells [115]. Here, FOXO1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.